A five lncRNA signature for prognosis prediction in hepatocellular carcinoma

被引:23
|
作者
Sun, Yongqiang [1 ]
Zhang, Fangfang [2 ]
Wang, Lifu [1 ]
Song, Xueai [1 ]
Jing, Jing [1 ]
Zhang, Fan [1 ]
Yu, Simiao [1 ]
Liu, Honghong [3 ]
机构
[1] 302 Mil Hosp China, Integrat Med Ctr, Beijing 100039, Peoples R China
[2] 302 Mil Hosp China, Outpatient Dept, Beijing 100039, Peoples R China
[3] 302 Mil Hosp China, Int Ctr Liver Dis Treatment, 100 West Fourth Ring Rd, Beijing 100039, Peoples R China
关键词
HCC; DELs; risk assessment model; co-expression network; prognosis; LONG NONCODING RNAS; LIPID-METABOLISM; POOR-PROGNOSIS; EXPRESSION; PROLIFERATION; PROGRESSION; CONTRIBUTES; SORAFENIB;
D O I
10.3892/mmr.2019.10203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study was conducted to screen prognosis-associated long-noncoding RNAs (lncRNAs) and a prognosis assessment model in hepatocellular carcinoma (HCC). lncRNA- and mRNA-sequencing data of early-stage HCC samples were downloaded from The Cancer Genome Atlas database. The samples were divided into training set and validation set. Differentially expressed lncRNAs (DELs) between poor prognosis and good prognosis samples were screened with DEseq and edgeR. Cox regression analysis was conducted to identify prognosis-associated lncRNAs in the training set. A prognosis risk assessment model was established to calculate the risk score for each patient in the training set, and the prognosis prediction function was tested and validated in the validation dataset. The connection between the risk assessment model and clinical features was analyzed. A co-expression network between lncRNAs and corresponding genes was constructed, and functional enrichment was performed for these genes. A total of 81 DELs were screened between poor and good prognosis samples in the training set, and 43 prognosis-associated lncRNAs were observed. Of these DELs, five were used to construct the risk assessment model (RP11-325L7.2, DKFZP434L187, RP11-100L22.4, DLX2-AS1 and RP11-104L21.3). Low-risk samples exhibited longer survival time compared with the high-risk samples. The five lncRNAs exhibited significant differences in expression levels between different prognosis groups. Risk score was an independent prognostic factor for HCC. In the entire set, the low-risk group demonstrated significantly better prognosis compared with the high-risk group, even across all age, sex and alcohol consumption subgroups. Nucleoside-triphosphatase regulator activity', GTPase regulator activity', enzyme binding', peroxisome proliferator-activated receptor signaling pathway' and fatty acid metabolism' were the most significantly enriched functional terms. The signature lncRNAs screened in this study may have constitute novel strategies and biomarkers that predict the prognosis of HCC, and these may also contribute to a deeper understanding of the mechanisms underlying HCC development.
引用
收藏
页码:5237 / 5250
页数:14
相关论文
共 50 条
  • [1] A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma
    Yan, Junhao
    Zhou, Chao
    Guo, Kuiyuan
    Li, Qian
    Wang, Zheng
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (01) : 213 - 223
  • [2] A Novel Five-Gene Signature for Prognosis Prediction in Hepatocellular Carcinoma
    Su, Lisa
    Zhang, Genhao
    Kong, Xiangdong
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma
    Bu, Xiaoyun
    Ma, Luyao
    Liu, Shuang
    Wen, Dongsheng
    Kan, Anna
    Xu, Yujie
    Lin, Xuanjia
    Shi, Ming
    [J]. CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [4] A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma
    Xiaoyun Bu
    Luyao Ma
    Shuang Liu
    Dongsheng Wen
    Anna Kan
    Yujie Xu
    Xuanjia Lin
    Ming Shi
    [J]. Cancer Cell International, 22
  • [5] Genomewide identification of a novel six-LncRNA signature to improve prognosis prediction in resectable hepatocellular carcinoma
    Wu, Ying
    Wang, Peng-Shuo
    Wang, Ben-Gang
    Xu, Lu
    Fang, Wan-Xia
    Che, Xiao-Fang
    Qu, Xiu-Juan
    Liu, Yun-Peng
    Li, Zhi
    [J]. CANCER MEDICINE, 2018, 7 (12): : 6219 - 6233
  • [6] Basement membrane-related lncRNA signature for the prognosis of hepatocellular carcinoma
    Xun, Shenmei
    Li, Xiaocui
    Zhuang, Qingyuan
    Zhu, Yefei
    Qu, Lili
    [J]. HELIYON, 2024, 10 (10)
  • [7] An m6A-Related lncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma
    Zhang, Zhenyu
    Wang, Fangkai
    Zhang, Jianlin
    Zhan, Wenjing
    Zhang, Gaosong
    Li, Chong
    Zhang, Tongyuan
    Yuan, Qianqian
    Chen, Jia
    Guo, Manyu
    Xu, Honghai
    Yu, Feng
    Wang, Hengyi
    Wang, Xingyu
    Kong, Weihao
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma
    Genhao Zhang
    Jianping Sun
    Xianwei Zhang
    [J]. Scientific Reports, 12
  • [9] Featured lncRNA-based signature for discriminating prognosis and progression of hepatocellular carcinoma
    Huiyuan Qiu
    Bo Jiang
    Yinqi Chen
    Zhaoyi Lin
    Wenjie Zheng
    Xiaolei Cao
    [J]. Journal of Applied Genetics, 2024, 65 : 355 - 366
  • [10] Correction to: Featured lncRNA‑based signature for discriminating prognosis and progression of hepatocellular carcinoma
    Huiyuan Qiu
    Bo Jiang
    Yinqi Chen
    Zhaoyi Lin
    Wenjie Zheng
    Xiaolei Cao
    [J]. Journal of Applied Genetics, 2024, 65 (2) : 415 - 415